BIOCHEMICAL MECHANISM OF AMYLOID DISEASE
淀粉样蛋白疾病的生化机制
基本信息
- 批准号:2145516
- 负责人:
- 金额:$ 9.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-05-01 至 1998-04-30
- 项目状态:已结题
- 来源:
- 关键词:SDS polyacrylamide gel electrophoresis acidity /alkalinity amyloid proteins amyloidosis calcium chemical kinetics conformation crosslink electron microscopy gene mutation hereditary peripheral nervous system disorder high performance liquid chromatography light scattering lysosomes mass spectrometry mutant nuclear magnetic resonance spectroscopy polymerase chain reaction polymerization protein denaturation protein folding protein reconstitution protein sequence protein structure proteolysis retinoid binding proteins thyroid hormone binding protein
项目摘要
The long term goal of this research is to understand the biochemical
mechanism of amyloid disease. Amyloid fibril formation refers to the
abnormal self-assembly of a normally soluble protein into an insoluble
cross beta-sheet quaternary structural form and is the causative agent in
amyloid disease. Understanding how a normally soluble protein is
transformed into amyloid fibrils is a critical part of understanding the
mechanism of this disease and is the focus of this proposal. The protein
transthyretin composes the amyloid fibrils in two different types of
human amyloid disease. The mechanism of transthyretin amyloid fibril
formation will be studied using an in vitro system that simulates the low
pH environment of the organelle where amyloid fibril formation is thought
to occur in vivo. The advantage of this in vitro system is its
simplicity, which will enable us to make careful measurements.
The acid-mediated partial denaturation of transthyretin is sufficient for
amyloid fibril formation in vitro. A structured acidic-form of
transthyretin appears to be the precursor that assembles into amyloid
fibrils. Transthyretin denaturation and amyloid fibril formation are
competitive processes that can now be studied individually due to the
discovery of an inhibitor which prevents amyloid fibril formation without
noticeably interfering with the denaturation pathway. Thus, in the
presence of amyloid inhibitor, transthyretin denaturation can be studied
and in the absence of inhibitor, fibril formation can be studied. It is
our priority to identify the nature of the transthyretin denaturation
intermediate competent to form fibrils. The denaturation pathway and the
ability of transthyretin variants to form fibrils will also be examined
in the course of these studies. Structurally based amyloid inhibitors
will be tested with regard to their ability to curb amyloid fibril
formation. Successful inhibitors in combination with kinetic and
thermodynamic denaturation and fibril formation studies should allow a
mechanism of fibril formation to be formulated.
Long term structural studies on certain acid induced conformations of
transthyretin will be initiated during these studies with the ultimate
goal of characterizing the denaturation intermediate that is the
precursor to amyloid fibrils.
这项研究的长期目标是了解生物化学
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFERY W KELLY其他文献
JEFFERY W KELLY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFERY W KELLY', 18)}}的其他基金
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
从药理学角度探讨轻链淀粉样变性的蛋白病成分
- 批准号:
10440457 - 财政年份:2021
- 资助金额:
$ 9.87万 - 项目类别:
Pharmacologic Lysosomal Flux Activators to Ameliorate Alzheimer's Disease and Related Dementias
药理学溶酶体通量激活剂可改善阿尔茨海默病和相关痴呆症
- 批准号:
10281046 - 财政年份:2021
- 资助金额:
$ 9.87万 - 项目类别:
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
从药理学角度探讨轻链淀粉样变性的蛋白病成分
- 批准号:
10186362 - 财政年份:2021
- 资助金额:
$ 9.87万 - 项目类别:
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
从药理学角度探讨轻链淀粉样变性的蛋白病成分
- 批准号:
10625486 - 财政年份:2021
- 资助金额:
$ 9.87万 - 项目类别:
Interplay of Intrinsic and Extrinsic Effects of N-glycans on Glycoproteostasis
N-聚糖对糖蛋白稳态的内在和外在影响的相互作用
- 批准号:
9520024 - 财政年份:2015
- 资助金额:
$ 9.87万 - 项目类别:
Interplay of Intrinsic and Extrinsic Effects of N-glycans on Glycoproteostasis
N-聚糖对糖蛋白稳态的内在和外在影响的相互作用
- 批准号:
8946941 - 财政年份:2015
- 资助金额:
$ 9.87万 - 项目类别:
Interplay of Intrinsic and Extrinsic Effects of N-glycans on Glycoproteostasis
N-聚糖对糖蛋白稳态的内在和外在影响的相互作用
- 批准号:
9116133 - 财政年份:2015
- 资助金额:
$ 9.87万 - 项目类别:
Discovering Small Molecule Activators of Stress-responsive Signaling
发现应激反应信号传导的小分子激活剂
- 批准号:
9904304 - 财政年份:2013
- 资助金额:
$ 9.87万 - 项目类别: